Q3 2020

Filed Nov 13, 2020 · 10-Q · 44 days after period end · 0001140361-20-025536

Q3 2020 · 10-Q

Revenue—

Net Income

-$3.98M

no prior Q3 2019 on file

EPS Diluted

-$0.13

no prior Q3 2019 on file

Operating Income-$174,671—

Free Cash Flowderived-$3,633,000—

Same quarter

no prior Q3 2019 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

ended Sep 30, 2020 · filed Nov 13, 2020 · 44 d after period end

Nautilus Biotechnology, Inc. · CIK 1808805 · Engraved from SEC EDGAR